Cytokinetics Inc CYTK
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if CYTK is a good fit for your portfolio.
News
-
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
-
Cytokinetics Reports Third Quarter 2023 Financial Results
-
Cytokinetics to Participate in Upcoming Investor Conferences
-
Cytokinetics to Announce Third Quarter Results on November 2, 2023
-
Cytokinetics Provides Update on Cardiac Myosin Inhibitor Programs and Plans to Build a Specialty Cardiology Franchise at Virtual Investor & Analyst Day
-
Cytokinetics Presents Baseline Characteristics From SEQUOIA-HCM at the HCM Society Scientific Sessions
-
Cytokinetics to Host Virtual Investor & Analyst Day on October 19, 2023
-
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Trading Information
- Previous Close Price
- $31.84
- Day Range
- $31.06–31.58
- 52-Week Range
- $26.00–47.47
- Bid/Ask
- $31.14 / $31.21
- Market Cap
- $3.06 Bil
- Volume/Avg
- 84,327 / 1.4 Mil
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 388.67
- Dividend Yield
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Cytokinetics Inc is a biotechnology company that develops muscle biology-driven treatments for diseases characterized by reduced muscle function, muscle weakness, and fatigue. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary disease. The treatment is based on small molecules specifically engineered to increase muscle function and contractility. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 576
- Website
- https://www.cytokinetics.com
Competitors
Valuation
|
Metric
|
CYTK
|
BMY
|
SNY
|
|---|---|---|---|
Price/Earnings (Normalized) | — | 6.46 | 11.80 |
Price/Book Value | — | 3.44 | 1.51 |
Price/Sales | 388.67 | 2.29 | 2.46 |
Price/Cash Flow | — | 6.38 | 10.65 |
Price/Earnings
CYTK
BMY
SNY
Financial Strength
|
Metric
|
CYTK
|
BMY
|
SNY
|
|---|---|---|---|
Quick Ratio | 6.97 | 0.99 | 0.34 |
Current Ratio | 7.22 | 1.18 | 1.22 |
Interest Coverage | −8.72 | 8.54 | 13.40 |
Quick Ratio
CYTK
BMY
SNY
Profitability
|
Metric
|
CYTK
|
BMY
|
SNY
|
|---|---|---|---|
Return on Assets (Normalized) | −51.17% | 16.88% | — |
Return on Equity (Normalized) | — | 51.13% | — |
Return on Invested Capital (Normalized) | −82.27% | 24.06% | — |
Return on Assets
CYTK
BMY
SNY
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Jtq | $464.6 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Hphgqy | $90.2 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Kgmkwqx | $86.9 Bil | |
SGEN
| Seagen Inc Ordinary Shares | Tvnzz | $40.5 Bil | |
MRNA
| Moderna Inc | Mxjlt | $29.6 Bil | |
ARGX
| argenx SE ADR | Xxfn | $29.3 Bil | |
BNTX
| BioNTech SE ADR | Hhr | $23.0 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Ysvxyx | $20.0 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Rblglq | $16.7 Bil | |
INCY
| Incyte Corp | Zgmyzr | $11.8 Bil |